Acessa Health Inc. Announces Presentations at the 46th Annual AAGL Global Congress on Minimally Invasive Gynecology

Acessa Health Logo

Acessa Health Inc. Announces Presentations at the 46th Annual AAGL Global Congress on Minimally Invasive Gynecology
Four-Year Data on the Acessa® System to be Presented

AUSTIN, Texas – Nov. 14, 2017 – – Acessa Health Inc., developer of the Acessa® System, an innovative laparoscopic radiofrequency ablation procedure for the treatment of uterine fibroids, announced today that four-year data along with community based evidence will be presented at the 46th Annual Global Congress on Minimally Invasive Gynecology Meeting, Nov. 12-16 in National Harbor, Greater Washington, D.C.

Tuesday, Nov. 14, 2017 from 1:09 PM – 1:15 PM
Title: Laparoscopic Radiofrequency Ablation (Lap-RFA) of Symptomatic Myomas and Laparoscopic Myomectomy (LM): Long-Term Outcomes from a Randomized Trial of Uterine-Sparing Techniques
Authors: Bernard Krämer, MD; Felix Neis, MD; Andrei Taran, MD; Dorit Schöller, MD; Keith B. Isaacson, MD; Sara Brucker, MD
Wednesday, Nov. 15, 2017 from 9:57 AM – 10:03 AM
Title: Benefits to Treatment of Symptomatic Fibroids with Laparoscopic Radiofrequency Ablation (Lap-RFA) Alone and Lap-RFA Plus Concomitant Therapeutic Surgery: A Retrospective Comparative Cohort Analysis
Author: Alan Greenberg, MD

“We are thrilled with the continued positive and long-term accumulation of clinical evidence associated with the Acessa procedure,” said Kim Rodriguez, chief executive officer, Acessa Health. “Our team is committed to transforming the delivery of women’s healthcare services focused on the treatment of uterine fibroids. Our continued collaboration with AAGL and clinical leaders across the field of minimally invasive gynecologic surgeons is critical to ensure women have broader access to the Acessa procedure.”

 

Symptomatic uterine fibroids are a significant societal and healthcare burden, and there is no clear consensus among medical professionals as to which procedural treatment is most appropriate for each symptomatic patient.1 With an estimated cumulative incidence of up to 70% and 80% in white and African American premenopausal women, respectively, severe symptoms occur in 15 to 30% of these patients.2 3

 

Hysterectomy remains a primary treatment option for women who have completed childbearing. It offers a complete solution to existing and recurrent fibroids and concomitant disorders, including adenomyosis and cervical neoplasia. However, adverse events are common among hysterectomy patients. One study reported a 28% risk of complications (such as major blood loss, wound complications, and febrile episodes) as well as a 10% risk of transfusion among Medicaid patients undergoing abdominal hysterectomy.4
Because of the invasiveness and observed risks associated with hysterectomy, many women delay treatment. Most patients express a desire for treatment that does not involve invasive surgery and preserves the uterus.3

 

About the Acessa System
The Acessa System is the only radiofrequency ablation system cleared by the U.S. Food and Drug Administration and CE marked for use in percutaneous, laparoscopic coagulation and ablation of soft tissue, including treatment of symptomatic uterine fibroids under laparoscopic ultrasound guidance. It has been the subject of 21 peer-reviewed publications across 750 study patients. In January 2017, the American Medical Association (AMA) issued a new Category 1 CPT code specifically for Laparoscopic Radiofrequency (RF) Ablation of Uterine Fibroids, paving the way for the Acessa procedure to become the standard of care for as many as 30 million women in the United States. For more information, visit AcessaProcedure.com.

 

About Acessa Health Inc.
Acessa Health is a women’s health innovator dedicated to advancing minimally invasive, uterine-sparing solutions for women with symptomatic fibroids. The company introduced the use of radiofrequency ablation for the treatment of uterine fibroids and is continuing to develop technologies that improve the lives of its patients. Acessa’s headquarters are in Austin, Texas.

 

[1] Havryliuk Y, Setton R, Carlow JJ, Shaktman BD. Symptomatic fibroid management: systematic review of the literature. J Soc Laparoenosc Surg.2017;21(3):e2017.00041
[2] Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol. 2003;188:100–7.
[3] Borah BJ, Nicholson WK, Bradley L, Stewart EA. The impact of uterine leiomyomas: a national survey of affected women. Am J Obstet Gynecol. 2013;209:319.e1–319.e20.
[4] Gliklich RE, Leavy MB, Velentgas P, et al. Identification of future research needs in the comparative management of uterine fibroid disease: a report on the priority-setting process, preliminary data analysis, and research plan. Report No. 31. Rockville, MD. Agency for Healthcare Research and Quality. 2011.

 

MEDIA CONTACT:
Diana Soltesz
Nobles Global Communications
diana@noblesgc.com
818-618-5634